InvestorsHub Logo
Followers 2
Posts 1472
Boards Moderated 0
Alias Born 07/20/2016

Re: hovacre post# 80786

Tuesday, 09/11/2018 8:42:01 PM

Tuesday, September 11, 2018 8:42:01 PM

Post# of 108192
Hov, with the albeit early data for PSA combo, median OS had not been reached in the combination arm after 13 months of follow-up and was 7.79 months in the monotherapy arm, wouldn't seem to be in Merck's interest to strike a deal now? It seems the almost doubling of median OS is pretty damn good.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ADXS News